Related Experiment Video
Updated: Feb 4, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
TRK Inhibition: A New Tumor-Agnostic Treatment Strategy
Shivaani Kummar1, Ulrik N Lassen2
1Division of Medical Oncology, Stanford University School of Medicine, 780 Welch Road, Rm CJ250L, Palo Alto, CA, 94305, USA. skummar@stanford.edu.
Abstract:
Oncogenic somatic chromosomal rearrangements involving the NTRK1, NTRK2 or NTRK3 genes (NTRK gene fusions) occur in up to 1% of all solid tumors, and have been reported across a wide range of tumor types. The fusion proteins encoded by such rearranged sequences have constitutively activated TRK tyrosine kinase domains, providing novel therapeutic anticancer targets. The potential clinical effectiveness of TRK inhibition in patients with tumors harboring NTRK gene fusions is being assessed in phase I and II trials of TRK inhibitors, such as larotrectinib and entrectinib. Clinical trial results have demonstrated that larotrectinib is generally well tolerated and has shown high response rates that are durable across tumor types. These data validate NTRK gene fusions as actionable genomic alterations. In this review, we present the clinical data, discuss the different approaches that might be used to routinely screen tumors to indicate the presence of NTRK gene fusions, explore the issue of acquired resistance to TRK inhibition, and reflect on the wider regulatory considerations for tumor site agnostic TRK inhibitor drug development.
Insights
NTRK gene fusions are found in various solid tumors, driving cancer growth. TRK inhibitors like larotrectinib show durable responses, validating these fusions as key therapeutic targets.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- NTRK gene fusions, present in up to 1% of solid tumors, lead to constitutively active TRK tyrosine kinases.
- These activated kinases represent promising therapeutic targets for anticancer drug development.
Purpose of the Study:
- To review clinical data on TRK inhibitors in tumors with NTRK gene fusions.
- To discuss screening methods, resistance mechanisms, and regulatory aspects of TRK inhibitor development.
Main Methods:
- Review of clinical trial data for TRK inhibitors (larotrectinib, entrectinib).
- Analysis of diagnostic approaches for NTRK gene fusions.
- Exploration of acquired resistance and regulatory considerations.
Main Results:
- Larotrectinib demonstrates good tolerability and high, durable response rates across tumor types.
- NTRK gene fusions are validated as actionable genomic alterations.
- TRK inhibition shows significant clinical effectiveness.
Conclusions:
- TRK inhibitors are effective in treating tumors with NTRK gene fusions.
- Routine screening and understanding resistance are crucial for optimizing TRK inhibitor therapy.
- Tumor-agnostic drug development for TRK inhibitors is supported by clinical data.
Related Concept Videos
Treatment Strategies for Psychological Disorders
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
Feedback Inhibition
Enzyme Inhibition
Inhibition of Cdk Activity
Persuasion Strategies
Coping Strategies: Problem Focused
For example, consider a student who struggles to understand their...

